Matteo M. Trucco
Expertise in
8
conditions

Dr. Matteo M. Trucco

Hematology | Oncology
9500 Euclid Avenue, 
Cleveland, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
8
conditions
9500 Euclid Avenue, 
Cleveland, OH 

Overview

Matteo Trucco is a Hematologist and an Oncologist practicing medicine in Cleveland, Ohio.

Dr. Trucco is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Osteosarcoma, Ewing Sarcoma, Adult Soft Tissue Sarcoma, and Bone Tumor.

He is actively involved in clinical research, co-authoring 33 peer reviewed articles and participating in 10 clinical trials. Dr. Trucco is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in FL

Hospital Affiliations

Cleveland Clinic

Languages Spoken

English
Italian
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

Cleveland Clinic Main Campus
9500 Euclid Avenue, Cleveland, OH 44195

Additional Areas of Focus

Dr. Trucco has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
Enrollment Status: Recruiting
Publish Date: September 04, 2026
Intervention Type: Drug
Study Drug: Oral Repotrectinib (TPX-0005)
Study Phase: Phase 1/Phase 2
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination With Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination With Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2026
Intervention Type: Drug, Procedure
Study Drugs: Nivolumab, Azacitidine
Study Phase: Phase 1
Phase II Study of Nab-Paclitaxel in Combination With Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
Phase II Study of Nab-Paclitaxel in Combination With Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
Enrollment Status: Completed
Publish Date: April 02, 2026
Intervention Type: Drug
Study Drugs: Nab-Paclitaxel, Gemcitabine
Study Phase: Phase 2
Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: November 26, 2025
Intervention Type: Drug
Study Drugs: Vincristine, Cyclophosphamide, Vinorelbine, Actinomycin D, Cyclophosphamide pill
Study Phase: Phase 2
A Phase 1 / 2, Dose Escalation Study of Intravenous TK216 in Patients With Relapsed or Refractory Ewing Sarcoma
A Phase 1 / 2, Dose Escalation Study of Intravenous TK216 in Patients With Relapsed or Refractory Ewing Sarcoma
Enrollment Status: Terminated
Publish Date: February 12, 2025
Intervention Type: Drug
Study Drug: TK216
Study Phase: Phase 1/Phase 2
A Phase II Trial of Concurrent Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma (ASPS) and Other Soft Tissue Sarcomas (STS)
A Phase II Trial of Concurrent Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma (ASPS) and Other Soft Tissue Sarcomas (STS)
Enrollment Status: Completed
Publish Date: July 12, 2024
Intervention Type: Drug
Study Drugs: Axitinib, Pembrolizumab
Study Phase: Phase 2
A Phase I Trial of Dendritic Cell Vaccination for Children and Adults With Sarcoma
A Phase I Trial of Dendritic Cell Vaccination for Children and Adults With Sarcoma
Enrollment Status: Completed
Publish Date: July 03, 2024
Intervention Type: Biological, Drug, Procedure
Study Drugs: Dendritic Cells Vaccine, Lysate of Tumor, Gemcitabine, Imiquimod
Study Phase: Phase 1
A Phase I/II Open-Label Trial of CPI-613® (Devimistat) Plus Hydroxychloroquine to Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue
A Phase I/II Open-Label Trial of CPI-613® (Devimistat) Plus Hydroxychloroquine to Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination With Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients With Relapsed or Refractory Solid Tumors
A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination With Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients With Relapsed or Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: May 20, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

33 Total Publications

Management of pediatric bone sarcomas.
Management of pediatric bone sarcomas.
Journal: Current opinion in pediatrics
Published: December 09, 2025
Similar Doctors
Expertise in
22
conditions
Dr. Jason N. Valent
Hematology | Oncology
Expertise in
22
conditions
Dr. Jason N. Valent
Hematology | Oncology
Referral may be required

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jason Valent is a Hematologist and an Oncologist practicing medicine in Cleveland, Ohio. Dr. Valent is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Primary Amyloidosis, Relapsed Refractory Multiple Myeloma (RRMM), Waldenstrom Macroglobulinemia, and Bone Marrow Aspiration. Dr. Valent is currently accepting new patients.

Expertise in
23
conditions
Dr. Brad L. Pohlman
Hematology | Oncology
Expertise in
23
conditions
Dr. Brad L. Pohlman
Hematology | Oncology
Referral may be required

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brad Pohlman is a Hematologist and an Oncologist practicing medicine in Cleveland, Ohio. Dr. Pohlman is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Pohlman is currently accepting new patients.

Expertise in
28
conditions
Dr. Anjali S. Advani
Hematology | Oncology
Expertise in
28
conditions
Dr. Anjali S. Advani
Hematology | Oncology
Referral may be required
Before you request

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
 (0.3 miles away)
866-223-8100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Anjali Advani is a Hematologist and an Oncologist practicing medicine in Cleveland, Ohio. Dr. Advani is highly rated in 28 conditions, according to our data. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Acute Myeloid Leukemia (AML), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Advani is board certified in American Board Of Internal Medicine, 2003. Dr. Advani is currently accepting new patients.

Frequently Asked Questions about Dr. Matteo M. Trucco

Is Dr. Matteo M. Trucco a top-rated expert for Osteosarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Matteo M. Trucco is classified as an Elite expert for Osteosarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Matteo M. Trucco specialize in?

While Dr. Matteo M. Trucco is a Hematology, they have specific expertise in Osteosarcoma, Ewing Sarcoma, and Adult Soft Tissue Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Matteo M. Trucco participate in research or clinical trials?

Yes. Dr. Matteo M. Trucco has published 33 articles and abstracts on conditions like Osteosarcoma. You can view a list of Dr. Matteo M. Trucco's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Matteo M. Trucco accept my insurance?

Dr. Matteo M. Trucco accepts most major insurance plans, including Humana and Managed Medicaid. We recommend calling the office directly to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Trucco's expertise for a condition
ConditionClose
View All 37 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile